Page 843 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

Index 821

Endoscopic biopsy, 160–161 Erythrocytosis Eye tumor, 675
Endoscopy, for intestinal tumors, 464–465 causes of, 103 Eyelid tumor, 675–678
clinical signs of, 676–677
tumors associated with, 99b, 103
Endostatin, 264
VetBooks.ir Endothelial cells, 50 “Escape phase,” of immunoediting hypothesis, diagnostic techniques and workup, 677
apoptosis of, 211
231
history of, 676–677
Endothelin-1 (ET-1), 597 Escherichia coli nitroreductase gene, 255 incidence of, 675, 676f–677f
Endothelin-A (ET-A), 597 Esophageal tumors, 449 natural behavior of, 675–676
Energy metabolism, cancer and, 48 comparative aspects of, 451 pathology of, 675–676
Enteral nutrition, 304–305 diagnostic tests and workup for, 449, 450f prognosis for, 677–678
Envelope protein, 22 incidence and risk factors for, 449 risk factors for, 675
Environmental carcinogen, 15–16 pathology and behavior of, 449 therapy for, 677–678
observational studies for, 87t–91t, 92 prognosis of, 450–451 Ezrin, 51, 533
Environmental tobacco smoke, 14 treatment options for, 450
observational studies for, 87t–91t, 92 Esophagostomy tube F
Eosinophil, 131f diets for, 305 FADD. see Fas-associated death domain
Eosinophilia, 103 placement of, 304–305 Familial cancer syndrome, 2
Ependymoma Estradiol-17β, 628–629 Familial retinoblastoma, 43
intracranial, 658t Estrogen, 18 Farber, Sydney, 182
in spinal cord, 666t overproduction, effects of, 628–629 Fas ligand (CD95 or FasL), 39
Epidemiology Estrus, dog spaying before, 604–605 Fas-associated death domain (FADD), 39, 39f
definition of, 81 Etoposide, 196 FDA. see Food and Drug Administration
evidence-based medicine approach and, Etretinate, 357 FDA Modernization Act, 345
81–97 Euphorbia fischeriana, 331–332 Feline acromegaly, 569–571, 570f
Epidermal growth factor, canine osteosarcoma Euthanasia, 312 Feline adrenocortical tumors, 573
and, 526 preparing family for, 318 Feline conjunctival melanomas, 676
Epidermal growth factor receptor (EGFR) Evidence-based medicine (EBM) approach Feline histiocytic diseases, 797
canine sinonasal tumors and, 495 application of, 81 feline histiocytic sarcoma, 797
overexpression of, 260 epidemiology and, 81–97 feline progressive histiocytosis, 792t, 797, 797f
small cell lung carcinoma and, 146 Excisional biopsy, 161 pulmonary Langerhans cell histiocytosis,
Epidermal tumor, identification of, 133 diagram of, 161f 792t, 797
Epidermis, tumors of, 133 for malignant melanoma of digital webbing, Feline hyperthyroidism, 577–578
Epigallocatechin gallate (EGCG), 309–310 369f Feline immunodeficiency, observational
Epigenetic event, cancer and, 10 Excisional sample, 61 studies for, 87t–91t
Epigenetic methylation, 10 Exocrine pancreas tumor, 135 Feline immunodeficiency virus (FIV), 25–26
Epipodophyllotoxins (etoposide and Exocrine pancreatic cancer, 451 cancer risk and, 93
teniposide), 196 Exon 8 and exon 11, 148 classification of, 25
Epithelial cell, benign/malignant tumors of, Experimental study, 82t transmission of, 25
64t Exploratory laparotomy treatment of, 25–26
Epithelial renal tumors, 652 for gastrinoma, 585 Feline immunodeficiency virus (FIV)-
Epithelial tumors, 355–362 for intestinal tumors, 465, 465f associated neoplasm, 25
cell characteristics in, 132–137 External beam radiation therapy, for nasal Feline injection-site sarcoma (FISS),
cytological identification of, 133 planum, cancer of, 493–494 epidemiological study on, 93
discrete round tumor, presenting as, 144 External validity, 82t Feline intestinal mast cell tumor, 396–397
ovarian tumors and, 597 Extraadrenal pheochromocytomas, 573 Feline leukemia virus (FeLV), 22–25
Epithelial-to-mesenchymal transition Extracapsular thyroidectomy, for feline cancer and, 23
(EMT), 7 hyperthyroidism, 579 FOCMA and, 23
cancer stem cells and, 50 Extracellular matrix, 131f neoplasia development and, 93
metastatic cascade and, 53 Extracorporeal intraoperative radiation neoplastic diseases caused by, 23–24
Epstein-Barr virus (EBV), 26 therapy, for canine osteosarcoma, 539 observational studies for, 87t–91t
Epulide “Extralabel” manner, 345 prevalence of, 23
of oral cavity, 435 Extranodal lymphoma, 724–729, 725b prevention and control of, 24
types of, 435 CNS lymphoma, 726–727 vaccination, 24–25
Equatorial plate, 36 cutaneous lymphoma, 727–728 Rickard strain of, 23
“Equilibrium phase,” of immunoediting general summary of prognosis for cats with subgroups of, 23
hypothesis, 231 lymphoma, 729 A, 23
erbB-2, 526 laryngeal/pharyngeal/tracheal lymphoma, B, 23
Erlotinib (Tarceva), 262 729, 729f C, 23
Error nasal lymphoma, 725–726, 726f transmission of, 22–25
in clinical trial ocular lymphoma, 729 treatment of, 24
bias, 344 renal lymphoma, 726, 727f biologic-response modifiers, 24
types of, 343 subcutaneous lymphoma, 728–729, 728f interferon, 24
at pathology laboratory, categories of, 75 Extravasation, 52f reverse transcriptase inhibitors, 24